"Baricitinib Improves Outcomes In Patients With Atopic Dermatitis" - Rob Volansky
Patients with moderate-to-severe atopic dermatitis experienced improvements in both clinical and patient-reported outcomes after treatment with baricitinib plus topical corticosteroids when compared with topical corticosteroids alone, according to phase 2 study data. “Importantly, in this study, patients had to fail four weeks of supervised therapy with a mid-potency topical corticosteroid before randomization, selecting for a difficult to treat patient population,” said lead investigator Emma Guttman-Yassky, MD, PhD, The Sol & Clara professor of dermatology, vice chair of research in the department of dermatology, and director of the center for excellence in eczema at the Icahn School of Medicine at Mount Sinai. “These new results suggest that baricitinib may have the potential to become an oral treatment option for patients suffering from atopic dermatitis who are unable to achieve adequate control with TCS.”
- Emma Guttman-Yassky, MD, PhD, The Sol & Clara Professor, Dermatology, Clinical Immunology, Medicine, Vice Chair, Research, Department of Dermatology, Director, The Center for Excellence in Eczema, Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai
Additional Coverage:
